These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33322557)

  • 21. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.
    Yao H; Cai H; Li T; Zhou B; Qin W; Lavillette D; Li D
    PLoS Pathog; 2021 Mar; 17(3):e1009328. PubMed ID: 33657135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2.
    Chouchane L; Grivel JC; Farag EABA; Pavlovski I; Maacha S; Sathappan A; Al-Romaihi HE; Abuaqel SW; Ata MMA; Chouchane AI; Remadi S; Halabi N; Rafii A; Al-Thani MH; Marr N; Subramanian M; Shan J
    JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33529170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding.
    Yang J; Lin S; Sun H; Chen Z; Yang F; Lin X; Guo L; Wang L; Wen A; Zhang X; Dai Y; He B; Cao Y; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
    Front Immunol; 2022; 13():820336. PubMed ID: 35663966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
    Wrapp D; De Vlieger D; Corbett KS; Torres GM; Wang N; Van Breedam W; Roose K; van Schie L; ; Hoffmann M; Pöhlmann S; Graham BS; Callewaert N; Schepens B; Saelens X; McLellan JS
    Cell; 2020 May; 181(5):1004-1015.e15. PubMed ID: 32375025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding Mechanism of Neutralizing Nanobodies Targeting SARS-CoV-2 Spike Glycoprotein.
    Golcuk M; Hacisuleyman A; Erman B; Yildiz A; Gur M
    J Chem Inf Model; 2021 Oct; 61(10):5152-5160. PubMed ID: 34581563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparing for the Future - Nanobodies for Covid-19?
    Sasisekharan R
    N Engl J Med; 2021 Apr; 384(16):1568-1571. PubMed ID: 33826817
    [No Abstract]   [Full Text] [Related]  

  • 29. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike.
    Fu Y; da Fonseca Rezende E Mello J; Fleming BD; Renn A; Chen CZ; Hu X; Xu M; Gorshkov K; Hanson Q; Zheng W; Lee EM; Perera L; Petrovich R; Pradhan M; Eastman RT; Itkin Z; Stanley TB; Hsu A; Dandey V; Sharma K; Gillette W; Taylor T; Ramakrishnan N; Perkins S; Esposito D; Oh E; Susumu K; Wolak M; Ferrer M; Hall MD; Borgnia MJ; Simeonov A
    PLoS One; 2022; 17(8):e0272364. PubMed ID: 35947606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.
    Favorskaya IA; Shcheblyakov DV; Esmagambetov IB; Dolzhikova IV; Alekseeva IA; Korobkova AI; Voronina DV; Ryabova EI; Derkaev AA; Kovyrshina AV; Iliukhina AA; Botikov AG; Voronina OL; Egorova DA; Zubkova OV; Ryzhova NN; Aksenova EI; Kunda MS; Logunov DY; Naroditsky BS; Gintsburg AL
    Front Immunol; 2022; 13():822159. PubMed ID: 35281053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
    Verkhivker G
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A potent synthetic nanobody with broad-spectrum activity neutralizes SARS-CoV-2 virus and the Omicron variant BA.1 through a unique binding mode.
    Zhao D; Liu L; Liu X; Zhang J; Yin Y; Luan L; Jiang D; Yang X; Li L; Xiong H; Xing D; Zheng Q; Xia N; Tao Y; Li S; Huang H
    J Nanobiotechnology; 2022 Sep; 20(1):411. PubMed ID: 36109732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanobody click chemistry for convenient site-specific fluorescent labelling, single step immunocytochemistry and delivery into living cells by photoporation and live cell imaging.
    Hebbrecht T; Liu J; Zwaenepoel O; Boddin G; Van Leene C; Decoene K; Madder A; Braeckmans K; Gettemans J
    N Biotechnol; 2020 Nov; 59():33-43. PubMed ID: 32659511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-HIV-1 Nanobody-IgG1 Constructs With Improved Neutralization Potency and the Ability to Mediate Fc Effector Functions.
    Schriek AI; van Haaren MM; Poniman M; Dekkers G; Bentlage AEH; Grobben M; Vidarsson G; Sanders RW; Verrips T; Geijtenbeek TBH; Heukers R; Kootstra NA; de Taeye SW; van Gils MJ
    Front Immunol; 2022; 13():893648. PubMed ID: 35651621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
    Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
    Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus.
    Dogan M; Kozhaya L; Placek L; Gunter C; Yigit M; Hardy R; Plassmeyer M; Coatney P; Lillard K; Bukhari Z; Kleinberg M; Hayes C; Arditi M; Klapper E; Merin N; Liang BT; Gupta R; Alpan O; Unutmaz D
    Commun Biol; 2021 Jan; 4(1):129. PubMed ID: 33514825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toolkit for Quickly Generating and Characterizing Molecular Probes Specific for SARS-CoV-2 Nucleocapsid as a Primer for Future Coronavirus Pandemic Preparedness.
    Sherwood LJ; Hayhurst A
    ACS Synth Biol; 2021 Feb; 10(2):379-390. PubMed ID: 33534552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.